Two Renowned Institutes Upgrade their Genome Analysis Facilities by Geniom Technology
News Aug 24, 2007
febit inc. has announced that the operational business of the company in the U.S. has been started successfully: Within the last months the first Geniom Instruments have been installed at the renowned US-institutes Prognosys Bioscience, Inc in San Diego (CA). and University of California in San Francisco (UCSF).
Prognosys is the first research site in the US that decided last spring to establish the Geniom microarray platform as genetic analysis tool in their laboratory.
Dr. Stefan Matysiak, Vice President & General Manger of febit inc., stated, “Prognosys is a crucial reference site for febit inc. Cooperations and clients like Marc Chee, founder and CEO of Prognosys, are extremely valuable in respect of a market characterized by particular dynamics and a high rate of innovation. We believe that in the near future the Geniom Technology will play an important role within the market of microarray analysis based on its high quality and unique flexibility.”
With the UCSF a very renowned and well equipped institute decided for Geniom to enhance the pool of technology at its Center for Advanced Technology (CAT). To get Geniom-supported research up and running as soon as possible, febit sent as a part of its customer service a team of specialists to train the UCSF laboratory team onsite, and optimizes the highly-advanced system to the scientists needs.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019